Stifel Financial’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$42.5M Sell
1,156,481
-111,219
-9% -$5.27M 0.04% 403
2025
Q4
$64.5M Buy
1,267,700
+348,328
+38% +$17.8M 0.06% 317
2025
Q3
$51M Sell
919,372
-227,577
-20% -$13.3M 0.05% 358
2025
Q2
$79.2M Sell
1,146,949
-40,568
-3% -$2.76M 0.08% 260
2025
Q1
$82.5M Sell
1,187,517
-329,650
-22% -$27.2M 0.09% 239
2024
Q4
$131M Sell
1,517,167
-240,123
-14% -$26M 0.14% 160
2024
Q3
$209M Sell
1,757,290
-14,742
-0.8% -$1.97M 0.22% 106
2024
Q2
$253M Buy
1,772,032
+74,716
+4% +$9.9M 0.28% 80
2024
Q1
$218M Buy
1,697,316
+72,189
+4% +$8.59M 0.25% 92
2023
Q4
$168M Buy
1,625,127
+99,677
+7% +$9.86M 0.21% 109
2023
Q3
$139M Buy
1,525,450
+34,770
+2% +$3.06M 0.2% 115
2023
Q2
$121M Sell
1,490,680
-514,998
-26% -$42.1M 0.17% 140
2023
Q1
$160M Sell
2,005,678
-413,146
-17% -$29.3M 0.23% 102
2022
Q4
$164M Sell
2,418,824
-25,310
-1% -$1.48M 0.25% 92
2022
Q3
$122M Sell
2,444,134
-35,556
-1% -$1.9M 0.2% 119
2022
Q2
$138M Buy
2,479,690
+134,324
+6% +$7.45M 0.22% 107
2022
Q1
$130M Buy
2,345,366
+259,788
+12% +$13.3M 0.18% 133
2021
Q4
$117M Buy
2,085,578
+60,016
+3% +$3.25M 0.15% 151
2021
Q3
$97.2M Buy
2,025,562
+84,398
+4% +$4.08M 0.14% 156
2021
Q2
$81.3M Buy
1,941,164
+70,712
+4% +$2.74M 0.12% 176
2021
Q1
$63.1M Buy
1,870,452
+267,598
+17% +$9.53M 0.1% 200
2020
Q4
$56M Buy
1,602,854
+48,250
+3% +$1.67M 0.1% 203
2020
Q3
$54M Buy
1,554,604
+24,934
+2% +$831K 0.11% 186
2020
Q2
$50.1M Buy
1,529,670
+704,814
+85% +$22.5M 0.12% 184
2020
Q1
$24.8M Buy
824,856
+198,788
+32% +$5.92M 0.07% 253
2019
Q4
$18.1M Buy
626,068
+60,510
+11% +$1.68M 0.04% 388
2019
Q3
$14.6M Buy
565,558
+53,848
+11% +$1.36M 0.04% 426
2019
Q2
$13.1M Sell
511,710
-4,554
-0.9% -$113K 0.03% 470
2019
Q1
$13.5M Buy
516,264
+33,578
+7% +$825K 0.04% 432
2018
Q4
$11.1M Sell
482,686
-126,830
-21% -$2.82M 0.04% 458
2018
Q3
$14.4M Sell
609,516
-53,436
-8% -$1.3M 0.04% 391
2018
Q2
$15.3M Sell
662,952
-52,406
-7% -$1.25M 0.05% 391
2018
Q1
$17.6M Sell
715,358
-11,804
-2% -$310K 0.06% 341
2017
Q4
$19.5M Buy
727,162
+4,766
+0.7% +$121K 0.06% 310
2017
Q3
$17.4M Sell
722,396
-23,542
-3% -$532K 0.06% 315
2017
Q2
$16M Buy
745,938
+18,060
+2% +$364K 0.06% 316
2017
Q1
$12.5M Sell
727,878
-239,608
-25% -$4.17M 0.05% 380
2016
Q4
$17.4M Sell
967,486
-291,040
-23% -$5.28M 0.07% 277
2016
Q3
$26.2M Sell
1,258,526
-409,776
-25% -$10.2M 0.12% 192
2016
Q2
$44.9M Sell
1,668,302
-26,756
-2% -$734K 0.21% 114
2016
Q1
$45.9M Buy
1,695,058
+23,454
+1% +$628K 0.24% 99
2015
Q4
$48.5M Sell
1,671,604
-164,056
-9% -$4.54M 0.25% 103
2015
Q3
$49.8M Sell
1,835,660
-33,222
-2% -$941K 0.28% 91
2015
Q2
$51M Buy
1,868,882
+143,616
+8% +$4.04M 0.26% 95
2015
Q1
$46M Buy
1,725,266
+52,034
+3% +$1.2M 0.25% 98
2014
Q4
$35.4M Buy
1,673,232
+1,547,536
+1,231% +$34.6M 0.2% 133
2014
Q3
$2.99M Buy
125,696
+61,452
+96% +$1.41M 0.03% 637
2014
Q2
$1.48M Buy
64,244
+10,512
+20% +$232K 0.01% 910
2014
Q1
$1.23M Buy
+53,732
New +$1.14M 0.01% 957

Other funds holding NVO

Stifel Financial's NVO Position: Q1 2026 in Review

Stifel Financial reduced its Novo Nordisk (NVO) stake by 8.8% in Q1 2026, selling an estimated $5.27M and leaving 1,156,481 shares worth $42.5M. The position accounts for 0.04% of the portfolio, ranked #403.

Stifel Financial first reported a position in NVO in Q1 2014 and has held it in 49 quarters since. The position peaked at $253M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Stifel Financial held 1,156,481 shares of Novo Nordisk worth $42.5M as of Q1 2026.
  • Stifel Financial sold 111,219 Novo Nordisk shares in Q1 2026, an estimated $5.27M.
  • Novo Nordisk made up 0.04% of Stifel Financial's portfolio in Q1 2026, its #403 holding.
  • Stifel Financial first reported a position in Novo Nordisk in Q1 2014 and has held it in 49 quarters since.
  • Stifel Financial's Novo Nordisk position peaked at $253M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.